. 2012 Oct 9;2:184–189. doi: 10.1016/j.rinim.2012.10.001

Table 1.

Proportion of participants with seroprotection and seroconversion in the various groups.

Dose	Baseline	28 days after injection		90 days after injection		180 days after injection		360 days after injection
	SP rate	SC rate	SP rate	SC rate	SP rate	SC rate	SP rate	SC rate	SP rate
	Number of participants (Percentage, 95% CI)
Placebo (n=81)	4 (4.9, 1.4–12.2)	4 (4.9, 1.4–12.2)	6 (7.4, 2.8–15.4)	2 (2.5, 0.3–8.6)	4 (4.9, 1.4–12.2)	17 (21.0, 12.7–31.5)	19 (23.5, 14.8–34.2)	–	–
15 μg (n=84)	4 (4.8, 1.3–11.8)	81 (96.4, 89.9–99.3)^a	80 (95.2, 88.3–98.7)^a	75 (89.3, 80.6–95.0)^a	72 (85.7, 76.4–92.4)^a	77 (91.7, 83.6–96.6)^a	75 (89.3, 80.6–95.0)^a	59 (70.2, 59.3–79.7)	39 (46.4, 35.5–57.7)
30 μg (n=87)	3 (3.4, 0.7–9.8)	86 (98.9, 93.8–100.0)^a	85 (97.7, 92.0–99.7)^a	80 (92.0, 84.1–96.7)^a	79 (90.8, 82.7–96.0)^a	83 (95.4, 88.6–98.7)^a	76 (87.4, 78.5–93.5)^a	65 (74.7, 64.3–83.4)	43 (49.4, 38.5–60.4)
45 μg (n=88)	2 (2.3, 0.3–8.0)	88 (100.0, 95.9–100.0)^a	86 (97.7, 92.0–99.7)^a	83 (94.3, 87.2–98.1)^a	82 (93.2, 85.8–97.5)^a	84 (95.5, 88.8–98.8)^a	80 (90.9, 82.9–96.0)^a	72 (95.5, 88.8–98.8)	49 (55.7, 44.7–66.3)

Seroprotection (SP) was defined as an HI titer of no less than 1:40; seroconversion (SC) was defined as an increase in the HI titer by a factor of four or more.

P<0.05 compared with the placebo.